EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

MabCure, Inc (MBCI) fair value: what the stock is really worth

We calculate from audited financials what MabCure, Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Aug 19, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Technology · US · ISIN US5540941029

MI MabCure, Inc logo Thin data Aug 19, 2026

MabCure, Inc

MBCI · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0003 · Fairly valued (+0.0%)
!Quality 37/100
!Weak Growth
!negative free cash flow
!Mixed vs. peers (3/6)
!Narrow moat 37/100
!Evidence only low, so the estimate is less certain
Watch MabCure, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0091 $0.0001 Fair Value $0.0003 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range $0.0001 – $0.0091 · fair‑value band $0.0003 – $0.0003 · the $0.0003 price screens below the $0.0003 fair value. Dashed = 300-day average. As of Aug 19, 2026.

Follow MabCure in your weekly email

Every Wednesday you see whether MabCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers.

Show more

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.

Stock analysis

MabCure, Inc (MBCI) currently trades at $0.0003, while our model-based Fair Value estimate is $0.0003, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the evidence level at low.

Scenario range: $0.0003 (bear) to $0.0003 (bull), the price of $0.0003 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Technology sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

MabCure, Inc reported revenue of $500K in FY2011 versus $0 in FY2008. Reported net income was −$12.5M in FY2011.

Key figures

Market cap $234 · EPS (TTM) $−0.0200 · Return on equity −125% · Return on assets (EBIT) −7.7% · Operating margin 45.3% · Revenue (TTM) $500K · Free cash flow −$62.7K · Net debt $115K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 40% below its 52-week high and 200% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Technology peers we cover trades at 10% fair-value upside, at 0%, MBCI screens richer than that median.

Fair Value models

Bear $0.0003 Fair Value $0.0003 Bull $0.0003
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0002 $0.0003 $0.0004 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.0002 $0.0003 $0.0004 51

Open the full fair value analysis →

Notify me when MBCI reaches fair value

Put MBCI on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 33 · Market factors (momentum, volatility) 35

Profitability 4
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 52
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 27
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2011 is a loss year, no rate is defined from a loss
not computed

Watch MBCI, get fair value alerts →

Compare MabCure, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Solar · 105 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Below median
Profitability
Return on assets −4.2% · Below median
Operating margin (TTM) 45.3% · Top 25%
Growth and dividend
Revenue growth 0.0% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 10
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 84
DIVIDEND (yield)0 · sector 26

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Solar stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
First Solar, Inc FSLR $176.93 $392.06 +122%
Nextpower Inc NXT $80.85 $88.94 +10%
Tongwei Co 600438 ¥11.12 ¥12.13 +9%
Waaree Energies Limited WAAREEENER ₹2,340 ₹2,709 +16%
Jinko Solar Co 688223 ¥3.75 ¥6.49 +73%
Hanwha Solutions Corporation 009830 29,200 KRW 9,611 KRW −67%
Hengdian Group 002056 ¥20.04 ¥31.86 +59%
CSI Solar Co 688472 ¥8.32 ¥4.88 −41%
Enphase Energy, Inc ENPH $30.91 $24.08 −22%
Premier Energies Limited PREMIERENE ₹896.40 ₹648.72 −28%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MabCure, Inc · Fair Value
$0.0003 +0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "MabCure, Inc Fair Value". https://www.fairvalue-calculator.com/stock/MBCI

Frequently asked questions

Is MabCure, Inc (MBCI) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of $0.0003 versus the last price from Sep 25, 2026 of $0.0003, about +0% upside (fairly valued).
What is the fair value of MBCI?
Our model-based fair value for MabCure, Inc is $0.0003 (as of Aug 19, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0003.
What is the quality score of MBCI?
MabCure, Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MabCure, Inc (MBCI)?
Our model-based price target is the fair value of $0.0003 (as of Aug 19, 2026) from 1 valuation models. Cautious scenario $0.0003, optimistic scenario $0.0003. It is a calculation from audited fundamentals, not an analyst target.
What is the MabCure, Inc stock forecast for 2026?
Our models put fair value at $0.0003, about +0% upside versus the last price from Sep 25, 2026 of $0.0003 (fairly valued). Cautious scenario $0.0003, optimistic scenario $0.0003. The calculation is refreshed regularly with new filings.
What is the revenue of MabCure, Inc (MBCI)?
MabCure, Inc reported trailing-twelve-month revenue of about $500K (latest available figure, as of Aug 19, 2026).
What is the intrinsic value of MabCure, Inc (MBCI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MabCure, Inc it is $0.0003 per share (as of Aug 19, 2026), against a price of $0.0003. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MabCure, Inc stock overvalued or undervalued in 2026?
As of Aug 19, 2026, MBCI trades below its calculated fair value: price $0.0003, fair value $0.0003, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MBCI?
No. The price is what the market pays today ($0.0003); the fair value is what the company's own numbers justify ($0.0003). For MabCure, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is MabCure, Inc worth?
The market values MabCure, Inc at about $234 (market capitalisation, as of Aug 19, 2026). Per share that is $0.0003; our models calculate a fair value of $0.0003 per share.
What do the bullish and bearish scenarios say about MBCI?
Our models span a range for MabCure, Inc: cautious scenario $0.0003, base $0.0003, optimistic $0.0003 per share (as of Aug 19, 2026, price $0.0003). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MabCure, Inc (MBCI)?
Balance-sheet figures for MabCure, Inc (as of Aug 19, 2026): return on equity −125.2%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MBCI from its 52-week high?
MabCure, Inc trades at $0.0003, about 40% below its 52-week high of $0.0005 and 200% above the low of $0.0001 (as of Sep 15, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0003 is for.
Which stocks are comparable to MabCure, Inc?
From the same area (Technology) we also value First Solar, Inc, Nextpower Inc, Tongwei Co, Waaree Energies Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MabCure, Inc stock attractive at the current price?
The data as of Aug 19, 2026: price $0.0003, calculated fair value $0.0003 (+0%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MBCI calculated?
We run MabCure, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0003, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. MabCure, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MabCure, Inc (MBCI)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0003. Our model-based fair value is $0.0003, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MabCure, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0003 to $0.0003), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of MabCure, Inc

How large is the market capitalisation of MabCure, Inc (MBCI)?
The market capitalisation of MabCure, Inc is $234. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of MabCure, Inc (MBCI)?
Earnings per share at MabCure, Inc are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of MabCure, Inc (MBCI)?
The return on equity (ROE) of MabCure, Inc is −125% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MabCure, Inc (MBCI)?
On an EBIT basis the return on assets of MabCure, Inc is −7.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MabCure, Inc (MBCI)?
The operating margin of MabCure, Inc is 45.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does MabCure, Inc (MBCI) generate?
The free cash flow of MabCure, Inc is −$62.7K (fiscal year 2011). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MabCure, Inc (MBCI) carry?
The net debt of MabCure, Inc is $115K (fiscal year 2011). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MabCure, Inc in the live analysis

One click puts MabCure, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.